Generic Semaglutide in Canada Delayed: Updated 2026 Timeline, Rejections, and Expected Prices

January 4, 2026 was a significant date for Canadians who pay out-of-pocket for semaglutide. That day, Novo Nordisk’s data exclusivity on the drug expired — making Canada the first major Western market where generic manufacturers could legally file for approval. Nine companies filed submissions. But the path from filing to pharmacy shelves has proven far more complex than early projections suggested.

Since our original publication, multiple developments have reshaped the timeline: Health Canada has issued rejections, manufacturers have revised their launch dates, and new entrants — including the original manufacturer — have changed the competitive landscape. This updated post reflects everything known as of February 22, 2026.

Data Exclusivity: What Expired and Why It Matters

In Canada, brand-name drugs receive a period of data exclusivity — typically eight years — during which generic manufacturers cannot reference the originator’s clinical data to obtain their own approval. Novo Nordisk’s semaglutide data exclusivity ran out on January 4, 2026.

This is not a patent expiry in the traditional sense; Novo Nordisk may still hold manufacturing and formulation patents. However, the data exclusivity lapse is the critical regulatory trigger that allows Health Canada to review generic submissions. Without it, those applications could not move forward regardless of patent status.

Canada is ahead of most Western markets on this front. The United States and European Union have longer exclusivity periods in certain categories, which is why Canadian generics could arrive before American equivalents.

Health Canada Review: Delays, Rejections, and the Approval Backlog

As of February 2026, Health Canada has received nine generic semaglutide submissions from multiple manufacturers. However, the review process has encountered significant friction.

Dr. Reddy’s Laboratories: Notice of Non-Compliance

On October 30, 2025, Dr. Reddy’s Laboratories received a Notice of Non-Compliance (NON) from Health Canada for its generic semaglutide submission. A NON requires the manufacturer to address identified deficiencies before the application can proceed. Industry analysts estimate this delays Dr. Reddy’s timeline by 8–12 months, pushing any potential approval well into 2027.

Health Canada’s Broader Approval Backlog

The Dr. Reddy’s rejection is not an isolated case. Health Canada is currently reviewing over 500 generic drug submissions across all categories. In the 2024–25 fiscal year, 73% of initial generic submissions received rejections (Notices of Non-Compliance or similar deficiency notices) before ultimately being approved or withdrawn. This high initial rejection rate underscores the rigour of Health Canada’s review process — but also means that timelines frequently extend beyond initial projections.

For generic semaglutide specifically, the review is further complicated by the fact that Novo Nordisk’s semaglutide is produced through biological processes, while some generic versions use chemical synthesis — a distinction that can affect the regulatory review path and documentation requirements.

GLP1Prices.ca is not affiliated with Health Canada and does not have advance knowledge of regulatory decisions. The information above is based on public records only.

Revised Timeline: What Changed

Early projections placed the first generic semaglutide approvals in “spring or summer 2026.” Several developments have pushed expectations back:

The most realistic expectation for the first generic semaglutide to reach Canadian pharmacy shelves is now Q3 2026 at the earliest, with broader market competition developing into late 2026 and 2027.

Who Is Making Generic Semaglutide in Canada?

The competitive landscape has expanded since our original publication. Here is what is publicly known about each manufacturer:

Sandoz

One of the larger generic drug companies operating in Canada, Sandoz originally indicated an expected launch in the first half of 2026. The company has since revised its expected launch to Q3 2026, pending Health Canada approval.

Dr. Reddy’s Laboratories

India-based Dr. Reddy’s received a Notice of Non-Compliance from Health Canada on October 30, 2025. The company must address the identified deficiencies and resubmit, adding an estimated 8–12 months to its timeline. A revised approval is not expected before 2027.

PharmaTher

On February 2, 2026, PharmaTher announced it is pursuing Health Canada approval for a generic semaglutide product. As a newer entrant, PharmaTher’s timeline will depend on when its submission is filed and the pace of Health Canada’s review.

Vimy Pharma

Vimy Pharma, a Toronto-based startup founded by former Novo Nordisk executives, is planning a made-in-Canada generic semaglutide. The company intends to manufacture the active pharmaceutical ingredient (API) at a facility in Edmonton, Alberta. If successful, Vimy would be one of the few companies producing semaglutide API domestically in Canada rather than importing it.

Other Applicants

Multiple additional companies with Canadian distribution infrastructure have filed submissions. The full list of applicants is not publicly disclosed by Health Canada until approvals are granted.

The number of approved manufacturers will directly affect price competition. A single approved generic typically commands prices around 25–40% below the branded product. When three or more manufacturers compete, prices historically drop further and faster.

Novo Nordisk’s Counter-Strategy: Plosbrio and Poviztra

While generic manufacturers navigate the approval process, Novo Nordisk has made its own competitive move. On December 22, 2025, Health Canada approved two new semaglutide products from Novo Nordisk:

• Plosbrio — identical formulation to Ozempic, new brand name, expected lower price
• Poviztra — identical formulation to Wegovy, new brand name, expected lower price

These are not generics. They are the same drug from the same manufacturer under new brand names — a strategy that allows Novo Nordisk to set lower price points without reducing the listed price of Ozempic or Wegovy. Health Canada has explicitly confirmed that Plosbrio and Poviztra “are not generic semaglutide products and have no connection to Health Canada’s review of the generic semaglutide submissions.”

For full details on Plosbrio and Poviztra, see our post on Plosbrio and Poviztra in Canada: Novo Nordisk’s Lower-Price Semaglutide, Explained.

New Market Entrant: Hims & Hers Expanding to Canada

Hims & Hers, the US-based digital health platform, has announced plans to expand to Canada in 2026 with the stated goal of selling generic semaglutide through its digital platform. If Hims & Hers enters the Canadian market, it would represent a new distribution channel — direct-to-consumer digital ordering with home delivery — alongside traditional brick-and-mortar pharmacies and existing Canadian online pharmacies.

Hims & Hers would be subject to the same Canadian pharmacy licensing requirements and Health Canada regulations as any other distributor. Specific pricing and launch timing for their Canadian operations have not been announced.

Expected Pricing: What the Numbers Could Look Like

Current out-of-pocket prices for branded Ozempic (semaglutide injection) in Canada range from approximately $220 to $265 per month, depending on the pharmacy and province. Some pharmacies charge dispensing fees on top of the drug cost, which can add $10–15 per fill.

Based on Canadian generic pricing patterns and early manufacturer signals, generic semaglutide could be priced 60–70% below the current branded rate once competition establishes itself. Updated estimates now place the range at approximately $40–$78 per month for comparable doses — tighter than our original $60–$100 estimate, reflecting increased competition from the growing number of manufacturers and Novo Nordisk’s own lower-priced authorized brands.

These are estimates based on historical Canadian generic pricing patterns and manufacturer signals. Actual prices will be determined by manufacturers and pharmacies after approval. GLP1Prices.ca will publish verified prices as soon as they are confirmed.

Province-to-Province Variations

Drug pricing in Canada is not uniform across provinces. Several factors create variation:

• Provincial formulary listing — If a province lists generic semaglutide on its public drug benefit formulary, publicly insured patients may access it at lower cost-sharing rates. Formulary listing timelines vary by province and typically happen after Health Canada approval, not simultaneously.
• Dispensing fees — Pharmacy dispensing fees vary by province and by individual pharmacy. Ontario’s cap on dispensing fees differs from Alberta’s, for example.
• Online pharmacy pricing — Licensed online pharmacies that serve multiple provinces often price competitively. They will be among the first sources GLP1Prices.ca contacts for generic pricing.

As with branded semaglutide, comparing prices by province will remain important even after generics launch. The cheapest generic in Ontario may not be the cheapest option in British Columbia.

Ozempic vs. Generic Semaglutide: What Is Changing

Generic semaglutide submissions are for the same active ingredient — semaglutide — in the same injectable form factor. Health Canada’s generic approval process requires manufacturers to demonstrate bioequivalence: the generic must deliver the same amount of active drug into the bloodstream, at the same rate, as the reference product.

The device (auto-injector pen) may differ between manufacturers. Patients switching to a generic would receive instructions for the specific pen design their pharmacy dispenses.

For a detailed look at current Ozempic pricing across Canadian pharmacies, see our drug-specific price page.

How GLP1Prices.ca Will Track Generic Prices

Our process for tracking generic semaglutide prices will be identical to how we track branded products today: we call pharmacies, check public online listings, record the price, and show the date it was verified.

We will not publish estimated or manufacturer-suggested prices as if they were real pharmacy prices. Every entry in our database requires a confirmed price from a specific pharmacy on a specific date.

When generic semaglutide prices go live on GLP1Prices.ca, you will be able to filter by province, sort by price, and see verified pricing side by side with branded alternatives.

If you want to be notified the moment we list the first generic price, sign up for our generic price alert. We send one email when prices are live — no ongoing marketing.

Key Dates and Events Timeline

What to Watch in the Months Ahead

• Health Canada notices of compliance for generic semaglutide applications
• Sandoz Q3 2026 launch progress and any further timeline changes
• Dr. Reddy’s resubmission status following their Notice of Non-Compliance
• PharmaTher and Vimy Pharma regulatory filing milestones
• Hims & Hers Canadian market entry and pharmacy licensing
• Novo Nordisk pharmacy launch dates for Plosbrio and Poviztra
• Provincial formulary listing announcements (these follow federal approval)
• Pharmacy chain announcements on stocking and pricing

GLP1Prices.ca will continue to update this post and our price tables as verified information becomes available. Bookmark this page or subscribe for alerts to stay current.